Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of phase II and III trials center around neurotransmitter receptors and Aβ mechanisms, while tau and inflammation drugs are more prominent in phase II, often featuring repurposed compounds.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, drug development landscape for combination therapy is becoming increasingly crowded with both symptomatic and disease-modifying applications.51”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The major mechanisms of action center around: 1) neurotransmitter receptors, including AChE, NMDA receptor, 5-hydroxytryptamine receptor, nicotinic α7 receptor, and adrenoceptor; 2) Aβ, including the reduction of Aβ production (such as γ-secretase inhibitors and modulators, BACE1 inhibitors, and α-secretase activators), prevention of Aβ aggregation, and enhancing Aβ clearance (vaccines and ant”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
MethodThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 3×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
BackgroundMethodNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Similarly, stage-dependent efficacy of anti-inflammatory agents, suggests that these treatments may be useful early in AD [90, 103].”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Further, new understanding of the multiple roles of microglia and factors that affect their function in the progression of AD [10, 11, 35, 56, 57], has potential to open vastly new therapeutic options and targets.”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“Further, new understanding of the multiple roles of microglia and factors that affect their function in the progression of AD [10, 11, 35, 56, 57], has potential to open vastly new therapeutic options and targets.”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 3×
“AD are acetylcholine esterase inhibitors, including tacrine (first approved treatment, withdrawn soon after because of reports of liver toxicity), donepezil (also approved for severe AD), rivastigmine (also approved for severe AD), and galantamine [1, 2].”
BackgroundInfluentialFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · cited 1×
“It has been reported that NFTs may form independently of A burden due to other neural death pathways [25, 29].”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“AAB-003 A ARIA and microhemorrhages [97] AN-1792 A Brain inflammation [98] Atabecestat BACE inhibitor Elevated liver enzymes [73] Avagacestat -secretase inhibitor Gastrointestinal and dermatological side effects; Nonmelanoma skin cancers reported; ARIA [77] Azeliragon RAGE inhibitor High dose was associated with confu…”
BackgroundMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“For example, early epidemiological studies of NSAIDs, such as ibuprofen, reported lower rates of AD among individuals who had been taking these drugs for chronic treatment of inflammatory conditions [51, 52].”
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 3×
“Other pathogenic mechanisms have been reported to be associated with the progression of AD [54, 55], and these potential treatments have been studied in animal models and clinical trials.”
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195
Self-citationAlzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004 · cited 1×
“Further, 213 new understanding of the multiple roles of microglia 214 and factors that affect their function in the progres215 sion of AD [10, 11, 35, 56, 57], has potential to open 216 vastly new therapeutic options and targets.”
Self-citationBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002 · cited 2×
“It has been shown that CSF A 42 is an indicator of early stages of the disease, while CSF tau indicates the extent of cognitive decline at later stages [23, 24].”
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · cited 1×
“Tau imaging studies using 127 18F T807 PET in patients with MCI and AD demen128 tia, reported high levels of tau in neocortex correlate 129 with high A burden [28].”
The Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834
Self-citationThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
Self-citationA phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · cited 1×
“AAB-003 A ARIA and microhemorrhages [97] AN-1792 A Brain inflammation [98] Atabecestat BACE inhibitor Elevated liver enzymes [73] Avagacestat -secretase inhibitor Gastrointestinal and dermatological side effects; Nonmelanoma skin cancers reported; ARIA [77] Azeliragon RAGE inhibitor High dose was associated with confu…”
BackgroundThe genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Self-citationŠimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., De Silva, R., Di Giovanni, G., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 703 · cited 1×
“tau phosphorylation, prevention of tau aggregation, and promotion of tau clearance by intracellular and extracellular proteolysis and phagocytosis, as well as anti-tau directed immunotherapies [30, 31].”
BackgroundA 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease
Park, J., Wetzel, I., Marriott, I., Dréau, D., D’Avanzo, C., Kim, D. Y., Tanzi, R. E., & Cho, H. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0175-4 · Cited by 644
Self-citationMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628 · cited 2×
“It has been reported that NFTs may form independently of A burden due to other neural death pathways [25, 29].”
BackgroundTownsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., & Selkoe, D. J. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.103754 · Cited by 619 · cited 1×
“of A oligomers, drives neuronal death and AD 73 pathogenesis [14, 15].”
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
for the SCarlet RoAD Investigators, Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0318-y · Cited by 567
Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511
Self-citationAlzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid ß-protein
Selkoe, D. J. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3111 · Cited by 466 · cited 1×
“The aggregation and extracellular deposition of A oligomers, drives neuronal death and AD pathogenesis [14, 15].”
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Self-citationBeale, A. D., Pedrazzoli, M., Gonçalves, B. D. S. B., Beijamini, F., Duarte, N. E., Egan, K. J., Knutson, K. L., Schantz, M. V., & Roden, L. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-05712-3 · Cited by 461
The aerobic diagenesis of Mesoproterozoic organic matter
Wang, X., Zhao, W., Zhang, S., Wang, H., Su, J., Canfield, D. E., & Hammarlund, E. U. (2018) · Scientific Reports · doi:10.1038/s41598-018-31378-6 · Cited by 428
A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease
The International Genomics of Alzheimer's Project, Huang, K.-L., Initiative, T. A. D. N., Marcora, E., Pimenova, A. A., Di Narzo, A. F., Kapoor, M., Jin, S. C., Harari, O., Bertelsen, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4587 · Cited by 423
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · cited 3×
“Drug Description/Target Results AAB-003 A ARIA and microhemorrhages [97] Janssen, Pfizer AN-1792 A Brain inflammation [98] Janssen, Pfizer Atabecestat BACE inhibitor Elevated liver enzymes [73] Janssen Avagacestat -secretase inhibitor Gastrointestinal and dermatological side effects; Nonmelanoma skin cancers reported;…”
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357 · cited 1×
“For example, increased flortaucipir binding has been shown to correlate with increased cognitive impairment in patients with A plaque [107].”
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352 · cited 1×
“In addition to subjects’ genetic make up, multiple other lifestyle factors including physical and mental exercise, heart disease, diabetes, lower education, and mental diseases are thought to accelerate AD progression [12, 13].”
BackgroundBapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0189-7 · Cited by 304
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298 · cited 2×
“The need to administer the 511 treatment frequently for several years, with high risk 512 of systemic toxicity, requires that an adequate dose is 513 selected early in the drug development phase [91].”
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 213 · cited 1×
“Since the typical annual change in CDR-SB reported for early AD patients is between 1-2 points [95, 96], the changes are small and require large number of subjects to reach statistical significance, even in cases when the drug is clinically effective in stabilizing cognitive decline.”
BackgroundDONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 195
Cummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D., Bell, J., Mancuso, J. Y., Kupiec, J. W., Sabbagh, M. N., van Dyck, C., Thomas, R. G., Aisen, P. S., & Study, F. T. A. D. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000364 · Cited by 187
A brief overview of amyloids and Alzheimer's disease
Ow, S., & Dunstan, D. E. (2014) · Protein Science · doi:10.1002/pro.2524 · Cited by 175 · cited 1×
“While A 145 consists of 36–42 amino acids, the human central 146 nervous system expresses six tau isoforms that com147 prise from 352 to 441 amino acids with four sequence 148 repeats in normal as compared to three sequence 149 repeats in AD [32, 33].”
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172 · cited 1×
“However, controlled clinical trials of ibuprofen at a dose of 400 mg/day showed no cognitive improvement and had known side effects [53].”
BackgroundBurstein, A. H., Sabbagh, M., Andrews, R., Valcarce, C., Dunn, I., & Altstiel, L. (2018) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.18 · Cited by 171 · cited 16×
“AZTherapies Azeliragon RAGE inhibitor (A and inflammation) Phase III (mild to moderate AD) Lack of efficacy; Tolerance issues at higher doses in a Phase II trial [41] Pfizer, TransTech Pharma CHF 5074 -secretase Two Phase II studies (amnestic or non-amnestic MCI) Discontinued CereSpir Celecoxib (Celebrex) NSAID Preven…”
InfluentialAtri, A., Frölich, L., Ballard, C., Tariot, P. N., Molinuevo, J. L., Boneva, N., Windfeld, K., Raket, L. L., & Cummings, J. L. (2018) · JAMA · doi:10.1001/jama.2017.20373 · Cited by 167 · cited 3×
“dine [60], Idalopirdine [61], and PF-05212377 [61], 265 failed to reach efficacy endpoints.”
Lee, G., & Leugers, C. J. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00004-7 · Cited by 165 · cited 1×
“While A consists of 36–42 amino acids, the human central nervous system expresses six tau isoforms that comprise from 352 to 441 amino acids with four sequence repeats in normal as compared to three sequence repeats in AD [32, 33].”
BackgroundTau-Based Treatment Strategies in Neurodegenerative Diseases
Schneider, A., & Mandelkow�, E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.006 · Cited by 158 · cited 1×
“extracellular proteolysis and phagocytosis, as well as 139 anti-tau directed immunotherapies [30, 31].”
The Amyloid Precursor Protein Is Developmentally Regulated and Correlated with Synaptogenesis
Moya, K. L., Benowitz, L. I., Schneider, G. E., & Allinquant, B. (1994) · Developmental Biology · doi:10.1006/dbio.1994.1055 · Cited by 157
A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, N. R., Thomas, R. G., Rissman, R. A., Brewer, J. B., Rafii, M. S., van Dyck, C. H., Jack, C. R., Sano, M., Knopman, D. S., Raman, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003904 · Cited by 157
Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores
Williams, M. M., Storandt, M., Roe, C. M., & Morris, J. C. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.005 · Cited by 156
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H., West, C., Robbins, J., & Niculescu, L. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 143
Becker, R. E., Greig, N. H., & Giacobini, E. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15213 · Cited by 140 · cited 2×
“At this stage, the disease progression path and rate are uncertain and show individual variability in part due to variability in dementia rating and patient populations [92, 93].”
BackgroundDonepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., Louis Tisserand, G., Touchon, J., Bonafe, A., Ousset, P. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 140
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Disease-modifying treatments for Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611404470 · Cited by 130 · cited 2×
“Other pathogenic mechanisms have been reported to be associated with the progression of AD [54, 55], and these potential treatments have been studied in animal models and clinical trials.”
BackgroundMemantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias
Molinuevo, J. L., Lladó, A., & Rami, L. (2005) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/153331750502000206 · Cited by 125 · cited 1×
“In addition, memantine, an uncompetitive (openchannel) N-methyl-D-aspartate (NMDA) antagonist with neuroprotective properties [4], is approved for treatment of moderate to severe AD.”
BackgroundSynaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases
Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., Hayden, E. Y., Teplow, D. B., Glabe, C., Albay, R., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.09.018 · Cited by 115
Alzheimer’s disease CSF biomarkers: clinical indications and rational use
Niemantsverdriet, E., Valckx, S., Bjerke, M., & Engelborghs, S. (2017) · Acta Neurologica Belgica · doi:10.1007/s13760-017-0816-5 · Cited by 114 · cited 1×
“geting amyloid- (A 42 or A 42/A 40), total tau 551 protein (T-tau) and phosphorylated tau (P-tau181) 552 [104].”
Grove, R., Harrington, C., Mahler, A., Beresford, I., Maruff, P., Lowy, M., Nicholls, A., Boardley, R., Berges, A., Nathan, P., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
Risk‐reducing effect of education in Alzheimer's disease
Sando, S. B., Melquist, S., Cannon, A., Hutton, M., Sletvold, O., Saltvedt, I., White, L. R., Lydersen, S., & Aasly, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2043 · Cited by 106
A Clinical Overview of Cholinesterase Inhibitors in Alzheimer’s Disease
Martin, F. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008688 · Cited by 100 · cited 1×
“approved for severe AD), and galantamine [1, 2].”
Self-citationZhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99
Self-citationGamberger, D., Lavrač, N., Srivatsa, S., Tanzi, R. E., & Doraiswamy, P. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06624-y · Cited by 95 · cited 1×
“At this stage, the disease progression path and rate are uncertain and show individual variability in part due to variability in dementia rating and patient populations [92, 93].”
BackgroundSelf-citationTargeting microglia for the treatment of Alzheimer’s disease
McGeer, P. L., & McGeer, E. G. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 88 · cited 1×
“In addition to pro-inflammatory response, microglial activation to phagocytic states is believed to have neuroprotective properties [37, 38].”
BackgroundHori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78
Self-citationA Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140291 · Cited by 71 · cited 1×
“PF-05212377 Antagonist of the serotonin 6 (5-HT6) receptor Phase II (mild to moderate AD) Lack of efficacy [62] Pfizer Xaliproden Serotonin 1A (5HT1-A) receptor antagonist Phase III (mild to moderate AD) Lack of efficacy [63] Sanofi ABT-288 Histamine H3 receptor antagonist Phase II (mild to moderate AD) Lack of effica…”
A Brief History of Alzheimer's Disease Gene Discovery
Tanzi, R. E. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129044 · Cited by 71
Self-citationSpotlight on the January 3 Issue
Gross, R. A. (2016) · Neurology · doi:10.1212/wnl.0000000000003450 · Cited by 69
Kile, S., Au, W., Parise, C., Rose, K., Donnel, T., Hankins, A., Chan, M., & Ghassemi, A. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311486 · Cited by 67
APP is required during an early phase of memory formation
Mileusnic, R., Lancashire, C. L., Johnston, A. N. B., & Rose, S. P. R. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.01344.x · Cited by 66
Mohs, R. C., Shiovitz, T. M., Tariot, P. N., Porsteinsson, A. P., Baker, K. D., & Feldman, P. D. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181aad585 · Cited by 65 · cited 1×
“Other clinical trials discontinued due to the lack of efficacy include Xaliproden (5HT1-A receptor antagonist) [63], Atomoxetine (norepinephrine uptake inhibitor approved for treatment of ADHD) [68], Dimebon (anti-histamine) [69], S47445 (agonist of AMPA receptors for glutamate) [70], and Sembragiline [71].”
BackgroundPhysiological Role of Amyloid Beta in Neural Cells: The Cellular Trophic Activity
C. Crdenas-Aguayo, M. D., C. Silva-Lucero, M. D., Cortes-Ortiz, M., Jimnez-Ramos, B., Gmez-Virgilio, L., Ramrez-Rodrguez, G., Vera- Arroyo, E., Fiorentino-Prez, R., Garca, U., Luna-Muoz, J., et al. (2014) · Neurochemistry · doi:10.5772/57398 · Cited by 60 · cited 1×
“trations of A (nanomolar and micromolar) are 75 considered neurotoxic, soluble A protein present in 76 low (picomolar) concentrations in normal brains, is 77 thought to have multiple functions including modu78 lating synaptic activity, memory formation, neuronal 79 survival, antioxidant activity, effects on Ca trans80…”
Delnomdedieu, M., Duvvuri, S., Li, D. J., Atassi, N., Lu, M., Brashear, H. R., Liu, E., Ness, S., & Kupiec, J. W. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0177-y · Cited by 59
Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals
Katsel, P., Tan, W., & Haroutunian, V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007642 · Cited by 55 · cited 1×
“showed using genetic and protein expression studies that development and progression of dementia depend on the age at onset and are different in demented younger and old aging populations; these features highlight the importance of the immune system in preventing cognitive decline [40].”
MethodDecourt, B., Drumm-Gurnee, D., Wilson, J., Jacobson, S., Belden, C., Sirrel, S., Ahmadi, M., Shill, H., Powell, J., Walker, A., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170117141330 · Cited by 55
Physiological levels of β-amyloid peptide promote PC12 cell proliferation
Luo, Y., Sunderland, T., Roth, G. S., & Wolozin, B. L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13087-1 · Cited by 49
Nave, S., Doody, R. S., Boada, M., Grimmer, T., Savola, J.-M., Delmar, P., Pauly-Evers, M., Nikolcheva, T., Czech, C., Borroni, E., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161309 · Cited by 48 · cited 1×
“Other clinical trials discontinued due to the lack of efficacy include Xaliproden (5HT1-A receptor antagonist) [63], Atomoxetine (norepinephrine uptake inhibitor approved for treatment of ADHD) [68], Dimebon (anti-histamine) [69], S47445 (agonist of AMPA receptors for glutamate) [70], and Sembragiline [71].”
BackgroundA Changing Perspective on the Role of Neuroinflammation in Alzheimer's Disease
Wilcock, D. M. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/495243 · Cited by 46 · cited 1×
“In addition to pro-inflammatory response, microglial activation to phagocytic states is believed to have neuroprotective properties [37, 38].”
BackgroundCano-Cuenca, N., Solís-García del Pozo, J. E., & Jordán, J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130872 · Cited by 42 · cited 1×
“Other clinical trials discontinued due to the lack of efficacy include Xaliproden (5HT1-A receptor antagonist) [63], Atomoxetine (norepinephrine uptake inhibitor approved for treatment of ADHD) [68], Dimebon (anti-histamine) [69], S47445 (agonist of AMPA receptors for glutamate) [70], and Sembragiline [71].”
BackgroundFullerton, T., Binneman, B., David, W., Delnomdedieu, M., Kupiec, J. W., LOCKWOOD, P. A., Mancuso, J. Y., Miceli, J. J., & Bell, J. S. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0368-9 · Cited by 33 · cited 1×
“PF-05212377 Antagonist of the serotonin 6 (5-HT6) receptor Phase II (mild to moderate AD) Lack of efficacy [62] Pfizer Xaliproden Serotonin 1A (5HT1-A) receptor antagonist Phase III (mild to moderate AD) Lack of efficacy [63] Sanofi ABT-288 Histamine H3 receptor antagonist Phase II (mild to moderate AD) Lack of effica…”
Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2009.00121.x · Cited by 30
Cutaneous Reflex Changes in Development and Aging
MAGLADERY, J. W., Teasdall, R. D., French, J. H., & BUSCH, E. S. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.00450010001001 · Cited by 15
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS
Aisen, P. S. S. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.62 · Cited by 14 · cited 1×
“, CDR-SB) at early and prodromal stages of the disease [93, 94].”
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Self-citationPotter, H., Woodcock, J. H., Boyd, T. D., Sillau, S., Bettcher, B. M., Daniels, J., Heffernan, K. S., & Gray, H. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.735 · Cited by 4
Gauthier, S. G., Feldman, H., Schneider, L. S. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J., Kook, K. A., Wischik, D., Schelter, B. O., Storey, J. M. D., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.650 · Cited by 3
New cerebrospinal fluid biomarkers in Alzheimer’s disease
Burchell, J. T., & Panegyres, P. K. (2017) · Future Neurology · doi:10.2217/fnl-2017-0009 · Cited by 3 · cited 1×
“Burchell and Panegyres reviewed several other biomarkers and assays including those involving BBB integrity, mitochondrial DNA, vascular endothelial growth factor, as well as immunological factors involved in AD pathogenesis [106].”
BackgroundNovák, P., Žilka, N., Kontseková, E., Ondrus, M., & Novák, M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.649 · Cited by 2
Research works printed but not linked: 12
- Tanzi RE, 2013, J Alzheimers Dis, 33, S5
- Wilcock DM, 2012, Int J Alzheimers Dis, 2012, 495243
- Lilly Press Release, Update on https://investor.lilly.com/node/39051/pdf 3 Clinical Trials of Lanabecestat for Alzheimer’s Disease. https://investor.lilly.com/node/39051/pdf, Posted June 12, 2018, Accessed February13, 2019.
- Coric V, 2012, Arch Neurol, 3, 1
- Biogen Press Release, Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer’s Disease, http://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials, Posted March 21, 2019, Accessed March 29, 2019.
- Biogen Press Release, Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months, http://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-positive-topline-results-final, Posted July 5, 2018, Accessed February 13, 2019.
- Lilly Press Release, Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, https://investor.lilly.com/static-files/9117f89a-0f6a-4dd8-a73e-97c108cf613d, Posted November 23, 2016, Accessed February 13, 2019.
- Gauthier S, 2016, Alzheimers Dement, 12, P351
- Zhang C, 2018, Sci Rep, 8, 1
- Aisen PS, 2015, J Prev Alzheimers Dis, 2, 82
- Lilly Press Release, Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer’s Disease, https://investor.lilly.com/news-releases/news-release-details/lilly-voluntarily-terminates-phase-ii-study-ly2886721-beta, Posted June 13, 2016, Accessed February 13, 2019.
- Pontecorvo MJ, 2017, Brain, 140, 748
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Current understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
“Furthermore, aggregation of Aβ could form oligomers and plaques, and the oligomers are recognized as the more toxic form of Aβ [3, 4].”
BackgroundInflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
“From a clinical point of view, the genetic diagnostics of inflammation that develops in the course of Alzheimer’s disease is also important [159].”
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
“Similar situation was with Octagam® (Phase II, completed, MCI/mild to moderate AD), where only transient improvement of patients was observed, without significant efficacy of the treatment (Elmaleh et al., 2019).”
MethodResultChallenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Metadata
- Authors
- Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E.
- Affiliations
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of Southern California (US)
- Harvard University (US)
- AZTherapies (United States) (US)
- Corresponding author
- Elmaleh, David R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-08-27
- Volume
- 71
- Issue
- 3
- Pages
- 715-732
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6839593
- OpenAlex
- W2971180542
- Cited by
- 129
- References
- 102
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 29 · 2020: 24 · 2019: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (acceptedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying drugs
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Humans, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.